维泰瑞隆,SIRONAX,北京维泰瑞隆,生物科技有限公司,退行性疾病,退行性神经疾病,老年痴呆,变革性疗法
Location: China, Beijing
Employees: 51-200
Total raised: $200M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 05.12.2024 | F-Prime Ca... | fprimecapi... |
| 22.05.2026 | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.08.2022 | Series B | $200M | - |
Mentions in press and media 5
| Date | Title | Description |
| 09.07.2025 | Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets | WALTHAM, Mass., July 9, 2025 /PRNewswire/ -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis un... |
| 02.08.2023 | Sironax Announces Closing of $200 Million Series B Financing | - |
| 05.08.2022 | Sironax Announces Closing of $200 Million Series B Financing | Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases. Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatment... |
| 02.08.2022 | Sironax Closes $200M Series B Financing | Sironax, a Beijing, China-based biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, closed a $200m Series B financing. The round was led by Gaorong... |
| 02.08.2022 | Sironax Announces Closing of $200 Million Series B Financing | Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and ... |